Cuprina Holdings (Cayman) Limited (CUPR)
| Market Cap | 13.31M -38.0% |
| Revenue (ttm) | 38,791 +3.3% |
| Net Income | -3.63M |
| EPS | -1.42 |
| Shares Out | 7.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 320,915 |
| Open | 1.900 |
| Previous Close | 1.950 |
| Day's Range | 1.820 - 1.940 |
| 52-Week Range | 1.445 - 14.800 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 24, 2026 |
About CUPR
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products... [Read more]
Financial Performance
In 2025, CUPR's revenue was 49,894, an increase of 3.26% compared to the previous year's 48,321. Losses were -4.67 million, 199.5% more than in 2024.
Financial numbers in SGD Financial StatementsNews
Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group
SINGAPORE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or the “Company”), a biomedical company developing and marketing products for the chronic wound...
Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter's Over-Allotment Option in Connection with Public Offering
SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic woun...
Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering
SINGAPORE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic woun...
Cuprina Holdings receives FDA clearance for Medifly Maggots
Cuprina Holdings (CUPR) announced that an indirectly wholly-owned subsidiary of the company, Cuprina Pte. has received 510 clearance from the FDA for Medifly Maggots, its medical-grade Lucilia cuprina...
Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product
SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, ...
Cuprina Holdings regains compliance with Nasdaq
Cuprina Holdings (CUPR) announced that on June 11 it has regained compliance with Nasdaq.
Cuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements
SINGAPORE, June 12, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wound...
Cuprina Holdings completes reverse stock split, requests Nasdaq panel hearing
Cuprina Holdings (CUPR) announced that it completed a reverse stock split on May 27, 2026, and requested a hearing before the Nasdaq Hearings Panel, in response to a staff determination…
Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing
SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds...
Cuprina Holdings (Cayman) Ltd trading halted, news pending
19:50 EDT Cuprina Holdings (CUPR) (Cayman) Ltd trading halted, news pending
Cuprina Holdings announces 1-for-8 share consolidation
Cuprina Holdings (CUPR) announced that it plans to implement a 1-for-8 share consolidation of its Class A ordinary shares and Class B ordinary shares, effective on or around May 27.
Cuprina Holdings announces 1-for-8 Share Consolidation
SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds...
Cuprina Holdings announces product classification from SFDA for MEDIFLY
Cuprina Holdings (CUPR) announced several strategic business developments, including a significant regulatory classification in Saudi Arabia and the expansion of its Medical and Scientific Advisory Bo...
Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board
SINGAPORE, March 11, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic woun...
Cuprina Holdings receives noncompliance notification from Nasdaq
Cuprina Holdings (CUPR) received a letter of noncompliance from The Nasdaq Stock Market, dated November 26, 2025, notifying the Company that based on Cuprina’s closing bid price for the last…
Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wound...
Cuprina Signs MOU with Singapore Biowaste Solutions to Integrate Medical Waste Management Technologies
SINGAPORE, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wound...
Cuprina to Present Live, Answer Questions, at Skyline Signature Series™ on October 8th, 2025, at 11:00 AM ET
Individual and institutional investors, advisors, and analysts are invited to attend Individual and institutional investors, advisors, and analysts are invited to attend
Cuprina Secures Exclusive Rights to Southeast Asia's First UNIDO/GEF- Demonstrated Medical Waste Recycling Technology
SINGAPORE, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and com...
Cuprina Holdings reaffirms commitment to shareholders amid stock volatility
Cuprina Holdings (CUPR) issued the following statement in response to recent unusual trading activity and speculation surrounding the Company. The company said, “Over the past week, the Company’s stoc...
Cuprina Holdings (Cayman) Ltd trading resumes
11:15 EDT Cuprina Holdings (CUPR) (Cayman) Ltd trading resumes
Cuprina Holdings (Cayman) Ltd trading halted, volatility trading pause
09:50 EDT Cuprina Holdings (CUPR) (Cayman) Ltd trading halted, volatility trading pause
Cuprina Holdings (Cayman) Ltd trading resumes
09:35 EDT Cuprina Holdings (CUPR) (Cayman) Ltd trading resumes
Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market
SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commerc...
Cuprina Provides Update on Research Studies with Three Leading Education Institutes
SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and comm...